Regulating the regulator: NF-κB signaling in heart

Journal of Molecular and Cellular Cardiology

Volumn 41, Issue 4, 2006, Pages 580-591

  Hall, Gentzon ^a   Hasday, Jeffery D ^a,b   Rogers, Terry B ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

Cardiomyocyte; Heart disease; Inflammation; Nuclear factor B; Post translational modification

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; CYTOKINE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR RELA;

ACETYLATION; APOPTOSIS; CYTOKINE RELEASE; DRUG EFFECT; ENZYME ACTIVITY; HEART FIBRILLATION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; INFLAMMATION; NITRATION; NITROSYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REACTION ANALYSIS; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; STRESS; UBIQUITINATION;

ACETYLATION; ANIMALS; CYTOSOL; GENE EXPRESSION REGULATION; HEART; HEART DISEASES; HUMANS; I-KAPPA B PROTEINS; MODELS, BIOLOGICAL; MYOCARDIUM; NF-KAPPA B; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 33748557190     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.07.006     Document Type: Review

References (180)

1. Aleshin A., Sawa Y., Ono M., Funatsu T., Miyagawa S., and Matsuda H. Myocardial protective effect of FR167653; a novel cytokine inhibitor in ischemic-reperfused rat heart. Eur. J. Cardiothorac. Surg. 26 (2004) 974-980
2. Anest V., Hanson J.L., Cogswell P.C., Steinbrecher K.A., Strahl B.D., and Baldwin A.S. A nucleosomal function for I kappa B kinase-alpha in NF-kappa B-dependent gene expression. Nature 423 (2003) 659-663
3. Arenzana-Seisdedos F., Turpin P., Rodriguez M., Thomas D., Hay R.T., Virelizier J.L., et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J. Cell Sci. 110 Pt 3 (1997) 369-378
4. Bae J.S., Jang M.K., Hong S.H., An W.G., Choi Y.H., Do Kim H., et al. Phosphorylation of NF-kappa B by calmodulin-dependent kinase IV activates anti-apoptotic gene expression. Biochem. Biophys. Res. Commun. 305 (2003) 1094-1098
5. Baeuerle P.A., and Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242 (1988) 540-546
6. Barancik M., Htun P., Strohm C., Kilian K., and Schaper W. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J. Cardiovasc. Pharmacol. 3 5 (2000) 474-483
7. Bates P.W., and Miyamoto S. Expanded nuclear roles for IkappaBs. Sci. STKE 254 (2004) e48
8. Belosjorow S., Schulz M., Gres P., Jansen J., Michel M., and Heusch G. Blockade of p38 MAP kinase abolishes ischemic preconditioning in pigs. Circulation 104 (2001) 100
9. Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72 (1993) 729-739
10. Brown M., McGuinness M., Wright T., Ren X., Wang Y., Boivin G.P., et al. Cardiac-specific blockade of NF-kappaB in cardiac pathophysiology: differences between acute and chronic stimuli in vivo. Am. J. Physiol.: Heart Circ. Physiol. 289 (2005) H466-H476
11. Bui N.T., Livolsi A., Peyron J.F., and Prehn J.H. Activation of nuclear factor kappaB and Bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IkappaBalpha. J. Cell Biol. 152 (2001) 753-764
12. Bundy D.L., and McKeithan T.W. Diverse effects of BCL3 phosphorylation on its modulation of NF-kappaB p52 homodimer binding to DNA. J. Biol. Chem. 272 (1997) 33132-33139
13. Buss H., Dorrie A., Schmitz M.L., Frank R., Livingstone M., Resch K., et al. Phosphorylation of serine 468 by GSK-3 beta negatively regulates basal p65 NF-kappa B activity. J. Biol. Chem. 279 (2004) 49571-49574
14. Chantome A., Pance A., Gauthier N., Vandroux D., Chenu J., Solary E., et al. Casein kinase II-mediated phosphorylation of NF-kappa B p65 subunit enhances inducible nitric-oxide synthase gene transcription in vivo. J. Biol. Chem. 279 (2004) 23953-23960
15. Chen L.F., and Greene W.C. Regulation of distinct biological activities of the NF-kappa B transcription factor complex by acetylation. J. Mol. Med. 81 (2003) 549-557
16. Chen L.F., Mu Y.J., and Greene W.C. Acetylation of ReIA at discrete sites regulates distinct nuclear functions of NF-kappa B. EMBO J. 21 (2002) 6539-6548
17. Colasanti M., and Persichini T. Nitric oxide: an inhibitor of NF-kappa B/Rel system in glial cells. Brain Res. Bull. 52 (2000) 155-161
18. Craig R., Wagner M., McCardle T., Craig A.G., and Glembotski C.C. The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-kappa B. J. Biol. Chem. 276 (2001) 37621-37629
19. Dawn B., Xuan Y.T., Marian M., Flaherty M.P., Murphree S.S., Smith T.L., et al. Cardiac-specific abrogation of NF-kappa B activation in mice by transdominant expression of a mutant I kappa B alpha. J. Mol. Cell. Cardiol. 33 (2001) 161-173
20. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone Jr. M.A., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96 (1995) 60-68
21. delaTorre A., Schroeder R.A., Bartlett S.T., and Kuo P.C. Differential effects of nitric oxide-mediated S-nitrosylation on p50 and c-jun DNA binding. Surgery 124 (1998) 137-141
22. delaTorre A., Schroeder R.A., Punzalan C., and Kuo P.C. Endotoxin-mediated S-nitrosylation of p50 alters NF-kappa B-dependent gene transcription in ANA-1 murine macrophages. J. Immunol. 162 (1999) 4101-4108
23. Deng W.G., and Wu K.K. Augmentation of NF-kappa B mediated gene expression by a positive p300 and p50 regulatory loop. FASEB J. 17 (2003) A173
24. Deng W.G., and Wu K.K. Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J. Immunol. 171 (2003) 6581-6588
25. Deng W.G., Zhu Y., and Wu K.K. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J. Biol. Chem. 278 (2003) 4770-4777
26. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., and Karin M. A cytokine-responsive I kappa B kinase that activates the transcription factor NF-kappa B. Nature 388 (1997) 548-554
27. Dobrzanski P., Ryseck R.P., and Bravo R. Both N- and C-terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motif. Mol. Cell. Biol. 13 (1993) 1572-1582
28. Duran A., Diaz-Meco M.T., and Moscat J. Essential role of RelA Ser311 phosphorylation by zeta PKC in NF-kappa B transcriptional activation. EMBO J. 22 (2003) 3910-3918
29. Feldman A.M., Combes A., Wagner D., Kadakomi T., Kubota T., Li Y.Y., et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J. Am. Coll. Cardiol. 35 (2000) 537-544
30. Fijen J.W., Zijlstra J.G., De Boer P., Spanjersberg R., Tervaert J.W.C., Van der Werf T.S., et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 124 (2001) 16-20
31. Fiorucci S., Distrutti E., Mencarelli A., Rizzo G., Di Lorenzo A.R., Baldoni M., et al. Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. J. Pharmacol. Exp. Ther. 309 (2004) 1174-1182
32. Fiorucci S., Mencarelli A., Meneguzzi A., Lechi A., Morelli A., Del Soldato P., et al. NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo role of nitric oxide. Circulation 106 (2002) 3120-3125
33. Fujita T., Nolan G.P., Liou H.C., Scott M.L., and Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 7 (1993) 1354-1363
34. Furia B., Deng L., Wu K.L., Baylor S., Kehn K., Li H., et al. Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins. J. Biol. Chem. 277 (2002) 4973-4980
35. Gaboury J., Woodman R.C., Granger D.N., Reinhardt P., and Kubes P. Nitric oxide prevents leukocyte adherence: role of superoxide. Am. J. Physiol. 265 (1993) H862-H867
36. Ganchi P.A., Sun S.C., Greene W.C., and Ballard D.W. I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding. Mol. Biol. Cell 3 (1992) 1339-1352
37. Ghosh S. NF-kappa B: A mediator of inflammatory responses. J. Vasc. Surg. 33 (2001) 1288
38. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell Suppl. 109 (2002) S81-S96
39. Ghosh S., May M.J., and Kopp E.B. NF-kappa B and rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16 (1998) 225-260
40. Grandel U., Fink L., Blum A., Heep M., Buerke M., Kraemer H.J., et al. Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts-Evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation 102 (2000) 2758-2764
41. Granger D.N., and Kubes P. Nitric oxide as antiinflammatory agent. Methods Enzymol. 269 (1996) 434-442
42. Graul A.I., and Mealy N.E. Annual update 2003: cardiovascular drugs. Drugs Future 28 (2003) 565-625
43. Grundstrom S., Anderson P., Scheipers P., and Sundstedt A. Bcl-3 and NFkappaB p50-p50 homodimers act as transcriptional repressors in tolerant CD4+ T cells. J. Biol. Chem. 279 (2004) 8460-8468
44. Guan H., Hou S., and Ricciardi R.P. DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit. J. Biol. Chem. 280 (2005) 9957-9962
45. Gupta S., Purcell N.H., Lin A.N., and Sen S. Activation of nuclear factor-kappa B is necessary for myotrophin-induced cardiac hypertrophy. J. Cell Biol. 159 (2002) 1019-1028
46. Gupta S., Young D., and Sen S. Activation of NF-kappa B during hypertrophy and heart failure in myotrophin overexpressed transgenic mice. Circulation 106 (2002) 200
47. Gupta S., Young D., and Sen S. Myotrophin-induced cardiac hypertrophy is influenced by PKC-mediated activation of both ERK and NF-kappa B signaling pathways. J. Mol. Cell. Cardiol. 36 (2004) 623-624
48. Hall G., Singh I.S., Hester L., Hasday J.D., and Rogers T.B. Inhibitor-kappaB Kinase-beta regulates LPS-induced TNF-alpha production in cardiac myocytes through NF-kappaB p65 subunit phosphorylation. Am. J. Physiol.: Heart Circ. Physiol. 289 5 (2005 (Nov.)) H2103-H2111
49. Haudek S.B., Bryant D.D., and Giroir B.P. Differential regulation of myocardial NF kappa B following acute or chronic TNF-alpha exposure. J. Mol. Cell. Cardiol. 33 (2001) 1263-1271
50. Haudek S.B., Spencer E., Bryant D.D., White D.J., Maass D., Horton J.W., et al. Overexpression o f cardiac I-kappa Balpha prevents endotoxin-induced myocardial dysfunction. Am. J. Physiol.: Heart Circ. Physiol. 280 3 (2001 (Mar.)) H926-H928
51. Haudek S.B., Bryant D.D., Horton J.W., and Giroir B.P. NF kappa B activation in mouse heart after LPS and or TNF alpha stimulation. Shock 11 (1999) 11
52. Hayden M.S., and Ghosh S. Signaling to NF-kappa B. Genes Dev. 18 (2004) 2195-2224
53. Heusch M., Lin L., Geleziunas R., and Greene W.C. The generation of nfkb2 p52: mechanism and efficiency. Oncogene 18 (1999) 6201-6208
54. Hou S., Guan H., and Ricciardi R.P. Phosphorylation of serine 337 of NF-kappaB p50 is critical for DNA binding. J. Biol. Chem. 278 (2003) 45994-45998
55. Hu J., and Colburn N.H. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappa B/p65 DNA binding. Mol. Cancer Res. 3 (2005) 100-109
56. Huang T.T., Kudo N., Yoshida M., and Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1014-1019
57. Huguet C., Crepieux P., and Laudet V. Rel/NF-kappa B transcription factors and I kappa B inhibitors: evolution from a unique common ancestor. Oncogene 15 (1997) 2965-2974
58. Janczewski A.M., Kadokami T., Lemster B., Frye C.S., McTiernan C.F., and Feldman A.M. Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alpha. Am. J. Physiol.: Heart Circ. Physiol. 284 (2003) H960-H969
59. Jang M.K., Goo Y.H., Sohn Y.C., Kim Y.S., Lee S.K., Kang H.J., et al. Ca2+/calmodulin-dependent protein kinase IV stimulates nuclear factor-kappa B transactivation via phosphorylation of the p65 subunit. J. Biol. Chem. 276 (2001) 20005-20010
60. Johnson C., Van Antwerp D., and Hope T.J. An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IkappaBalpha. EMBO J. 18 (1999) 6682-6693
61. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev., Drug Discov. 3 (2004) 17-26
62. Kato T., Sano M., Miyoshi S., Sato T., Hakuno D., Ishida H., et al. Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. Circ. Res. 87 (2000) 937-945
63. Kishore N., Sommers C., Mathialagan S., Guzova J., Yao M., Hauser S., et al. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J. Biol. Chem. 278 (2003) 32861-32871
64. Knuefermann P., Chen P., Baumgarten G., and Sivasubramanian N. Myo/V1 (myotrophin) regulates the transcriptional activity of NF-kappa B through dimer reorganization. Circulation 102 (2000) 144-145
65. Knuefermann P., Chen P., Misra A., Shi S.P., Abdellatif M., and Sivasubramanian N. Myotrophin/V-1, a protein up-regulated in the failing human heart and in postnatal cerebellum, converts NF kappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers. J. Biol. Chem. 277 (2002) 23888-23897
66. Koike N., Takeyoshi I., Ohki S., Tokumine M., Matsumoto K., and Morishita Y. Effects of adding p38 mitogen-activated protein-kinase inhibitor to Celsior solution in canine heart transplantation from non-heart-beating donors. Transplantation 77 (2004) 286-292
67. Kopp E., and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 (1994) 956-959
68. Kubes P., Kurose I., and Granger D.N. NO donors prevent integrin-induced leukocyte adhesion but not P-selectin-dependent rolling in postischemic venules. Am. J. Physiol. 267 (1994) H931-H937
69. Kubota T., McTiernan C.F., Frye C.S., Slawson S.E., Lemster B.H., Koretsky A.P., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 81 (1997) 627-635
70. Kubota T., Miyagishima M., Frye C.S., Alber S.M., Bounoutas G.S., Kadokami T., et al. Overexpression of tumor necrosis factor-alpha activates both anti- and pro-apoptotic pathways in the myocardium. J. Mol. Cell. Cardiol. 33 (2001) 1331-1344
71. Latimer M., Ernst M.K., Dunn L.L., Drutskaya M., and Rice N.R. The N-terminal domain of IkappaB alpha masks the nuclear localization signal(s) of p50 and c-Rel homodimers. Mol. Cell. Biol. 18 (1998) 2640-2649
72. Lee S.H., and Hannink M. Molecular mechanisms that regulate transcription factor localization suggest new targets for drug development. Adv. Drug Delivery Rev. 55 (2003) 717-731
73. Lemke L.E., Bloem L.J., Fouts R., Esterman M., Sandusky G., and Vlahos C.J. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart. J. Mol. Cell. Cardiol. 33 (2001) 1527-1540
74. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor-necrosis-factor in severe chronic heart-failure. N. Engl. J. Med. 3 23 (1990) 236-241
75. Li G., Labruto F., Sirsjo A., Chen F., Vaage J., and Valen G. Myocardial protection by remote preconditioning: the role of nuclear factor kappa-B p105 and inducible nitric oxide synthase. Eur. J. Cardio-thorac. Surg. 26 (2004) 968-973
76. Li M., Georgakopoulos D., Lu G., Hester L., Kass D.A., Hasday J., et al. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 111 (2005) 2494-2502
77. Li Y.H., Ha T.Z., Chen Q., McMullen J.R., Kelley J., Williams D., et al. Inhibiting NF kappa B activation attenuates the development of cardiac hypertrophy. FASEB J. 18 (2004) A1090
78. Li Y.H., Ha T.Z., Gao X., Kelley J., Williams D.L., Browder I.W., et al. NF-kappa B activation is required for the development of cardiac hypertrophy in vivo. Am. J. Physiol.: Heart Circ. Physiol. 87 (2004) H1712-H1720
79. Lin L., and Ghosh S. A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol. Cell. Biol. 16 (1996) 2248-2254
80. Lindemann S., Sharafi M., Spiecker M., Buerke M., Fisch A., Grosser T., et al. NO reduces PMN adhesion to human vascular endothelial cells due to downregulation of ICAM-1 mRNA and surface expression. Thromb. Res. 97 (2000) 113-123
81. London B., Baker L.C., Lee J.S., Shusterman V., Choi B.R., Kubota T., et al. Calcium-dependent arrhythmias in transgenic mice with heart failure. Am. J. Physiol.: Heart and Circ. Physiol. 284 (2003) H431-H441
82. Luss H., Schmitz W., and Neumann J. A proteasome inhibitor confers cardioprotection. Cardiovasc. Res. 54 (2002) 140-151
83. Madrid L.V., Mayo M.W., Reuther J.Y., and Baldwin A.S. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the I kappa B kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 276 (2001) 18934-18940
84. Madrid L.V., Wang C.Y., Guttridge D.C., Schottelius A.J.G., Baldwin A.S., and Mayo M.W. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappa B. Mol. Cell. Biol. 20 (2000) 1626-1638
85. Malave H.A., Lee-Jackson D., Samuels P.D., Smith D.K., Blaustein A.S., and Mann D.L. Elevated circulating levels of tumor necrosis factor correlate with cardiac remodeling in patients with heart failure. J. Am. Coll. Cardiol. 35 (2000) 195A
86. Malave H.A., Taylor A.A., Lee-Jackson D., and Mann D.L. Elevated circulating levels of tumor necrosis factor correlate with depressed heart rate variability in patients with heart failure. Circulation 100 (1999) 206
87. Mann D.L. Tumor necrosis factor and viral myocarditis-The fine line between innate and inappropriate immune responses in the heart. Circulation 103 (2001) 626-629
88. Marshall H.E., Hess D.T., and Stamler J.S. S-nitrosylation: physiological regulation of NF-kappaB. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8841-8842
89. Marshall H.E., and Stamler J.S. Nitrosative stress-induced apoptosis through inhibition of NF-kappa B. J. Biol. Chem. 277 (2002) 34223-34228
90. Martin A.G., and Fresno M. Tumor necrosis factor-alpha activation of NF-kappa B requires the phosphorylation of Ser-471 in the transactivation domain of c-Rel. J. Biol. Chem. 275 (2000) 24383-24391
91. Matsumori A., Nunokawa Y., Yamaki A., Yamamoto K., Hwang M.W., Miyamoto T., et al. Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-kappa B inhibitor. Eur. J. Heart Fail. 6 (2004) 137-144
92. Matthews J.R., Botting C.H., Panico M., Morris H.R., and Hay R.T. Inhibition of NF-kappa B DNA binding by nitric oxide. Nucleic Acids Res. 24 (1996) 2236-2242
93. Maulik N., Engelman R.M., Rousou J.A., Flack III J.E., Deaton D., and Das D.K. Ischemic preconditioning reduces apoptosis by upregulating anti-death gene Bcl-2. Circulation 100 (1999) II369-II375
94. Maulik N., Sato M., Price B.D., and Das D.K. An essential role of NF kappa B in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett. 429 (1998) 365-369
95. May M.J., D'Acquisto F., Madge L.A., Glockner J., Pober J.S., and Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289 (2000) 1550-1554
96. Meiners S., Hocher B., Weller A., Laule M., Stangl V., Guenther C., et al. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 44 (2004) 471-477
97. Meiners S., Laule M., Rother W., Guenther C., Prauka I., Muschick P., et al. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 105 (2002) 483-489
98. Meldrum D.R. Mechanisms of cardiac preconditioning: ten years after the discovery of ischemic preconditioning. J. Surg. Res. 73 (1997) 1-13
99. Meldrum D.R. Tumor necrosis factor in the heart. Am. J. Physiol.: Regul. Integr. Comp. Physiol. 43 (1998) R577-R595
100. Mercurio F. The IKK signalsome: a multi-protein signaling complex regulating NF-kappa B activation. FASEB J. 12 (1998) A1302
101. Mercurio F., Murray B.W., Shevchenko A., Bennett B.L., Young D.B., Li J.W., et al. I kappa B kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol. Cell. Biol. 19 (1999) 1526-1538
102. Mercurio F., Zhu H.Y., Murray B.W., Shevchenko A., Bennett B.L., Li J.W., et al. IKK-1 and IKK-2: cytokine-activated I kappa B kinases essential for NF-kappa B activation. Science 278 (1997) 860-866
103. Miller B.S., and Zandi E. Complete reconstitution of human IkappaB kinase (IKK) complex in yeast. Assessment of its stoichiometry and the role of IKKgamma on the complex activity in the absence of stimulation. J. Biol. Chem. 276 (2001) 36320-36326
104. Morgan E.N., Boyle E.M., Yun W., Griscavage-Ennis J.M., Farr A.L., Canty T.G., et al. An essential role for NF-kappa B in the cardioadaptive response to ischemia. Ann. Thorac. Surg. 68 (1999) 377-382
105. Morishita R., Sugimoto T., Aoki M., Kida I., Tomita N., Moriguchi A., et al. In vivo transfection of cis element "decoy" against nuclear factor-kappa B binding site prevents myocardial infarction. Nat. Med. 3 (1997) 894-899
106. Nakano A., Cohen M.V., Critz S., and Downey J.M. SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Bas. Res. Cardiol. 95 (2000) 466-471
107. Newman W.H., Castresana M.R., Erceg S.K., and Warejcka D.J. Aspirin inhibits bacterial lipopolysaccharide (LPS) stimulated release of tumor necrosis factor alpha (TNF-alpha) from the isolated rat heart. Crit. Care Med. 27 (1999) A46
108. Nolan G.P., Fujita T., Bhatia K., Huppi C., Liou H.C., Scott M.L., et al. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol. Cell. Biol. 13 (1993) 3557-3566
109. Norman D.A., Yacoub M.H., and Barton P.J. Nuclear factor NF-kappa B in myocardium: developmental expression of subunits and activation by interleukin-1 beta in cardiac myocytes in vitro. Cardiovasc. Res. 39 (1998) 434-441
110. Okazaki T., Sakon S., Sasazuki T., Sakurai H., Doi T., Yagita H., et al. Phosphorylation of serine 276 is essential for p65 NF-kappa B subunit-dependent cellular responses. Biochem. Biophys. Res. Commun. 300 (2003) 807-812
111. Onai Y., Suzuki J., Kakuta T., Maejima Y., Haraguchi G., Fukasawa H., et al. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc. Res. 63 (2004) 51-59
112. Oral H., Kapadia S., Nakano M., TorreAmione G., Lee J., Leejackson D., et al. Tumor-necrosis-factor-alpha and the failing human heart. Clin. Cardiol. 18 (1995) 20-27
113. Pan J.L., and Mcever R.P. Regulation of the human P-selectin promoter by Bcl-3 and specific homodimeric members of the Nf-kappa-B/Rel family. J. Biol. Chem. 270 (1995) 23077-23083
114. Pan X.H., Baker L., Lee J.S., Kubota T., Feldman A.M., Salama G., et al. Atrial and ventricular arrhythmias in transgenic mice with myocardial expression of TNF-alpha. Circulation 98 (1998) 745
115. Park S.W., Huq M.D., Hu X., and Wei L.N. Tyrosine nitration on p65: a novel mechanism to rapidly inactivate nuclear factor-{kappa}B. Mol. Cell Proteomics 4 (2005) 300-309
116. Pelzer T., Neumann M., de Jager T., Jazbutyte V., and Neyses L. Estrogen effects in the myocardium: inhibition of NF-kappaB DNA binding by estrogen receptor-alpha and -beta. Biochem. Biophys. Res. Commun. 286 (2001) 1153-1157
117. Peng H.B., Spiecker M., and Liao J.K. Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J. Immunol. 161 (1998) 1970-1976
118. Persoons J.H., Schornagel K., Tilders F.F., De Vente J., Berkenbosch F., and Kraal G. Alveolar macrophages autoregulate IL-1 and IL-6 production by endogenous nitric oxide. Am. J. Respir. Cell Mol. Biol. 14 (1996) 272-278
119. Pineda-Molina E., and Lamas S. Nitric oxide as a regulator of gene expression: studies with the transcription factor proteins cJun and p50. BioFactors 15 (2001) 113-115
120. Podolin P.L., Callahan J.F., Bolognese B.J., Li Y.H., Carlson K., Davis T.G., et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J. Pharmacol. Exp. Ther. 312 (2005) 373-381
121. Poljak L., Carlson L., Cunningham K., Kosco-Vilbois M.H., and Siebenlist U. Distinct activities of p52/NF-kappa B required for proper secondary lymphoid organ microarchitecture: functions enhanced by Bcl-3. J. Immunol. 163 (1999) 6581-6588
122. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., and Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6668-6673
123. Qing M., Schumacher K., Heise R., Woltje M., Vazquez-Jimenez J.F., Richter T., et al. Intramyocardial synthesis of pro- and anti-inflammatory cytokines in infants with congenital cardiac defects. J. Am. Coll. Cardiol. 41 (2003) 2266-2274
124. Quivy V., and Van Lint C. Regulation at multiple levels of NF-kappa B-mediated transactivation by protein acetylation. Biochem. Pharmacol. 68 (2004) 1221-1229
125. Ravingerova T., Barancik M., and Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol. Cell. Biochem. 247 (2003) 127-138
126. Regula K.M., Ens K., and Kirshenbaum L.A. IKK beta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes. J. Biol. Chem. 277 (2002) 38676-38682
127. Rossoni G., Bernareggi M., Del Soldato P., and Berti F. A new nitroaspirin, NCX 4016, prevents postischemic ventricular dysfunction in perfused rabbit heart. Thromb. Haemost. 840 (1999)
128. Rossoni G., Berti M., Colonna V.D., Bernareggi M., Del Soldato P., and Berti F. Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit. Ital. Heart J. 1 (2000) 146-155
129. Rossoni G., Berti M., Del Soldato P., and Berti F. The new nitroderivative of aspirin, NCX 4016, displays protectant activity against myocardial infarct in the rabbit. Thromb. Haemost. 840 (1999)
130. Ryo A., Suizu F., Yoshida Y., Perrem K., Liou Y.C., Wulf G., et al. Regulation of NF-kappa B signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 12 (2003) 1413-1426
131. Sakaguchi T., Sawa Y., Fukushima N., Nishimura M., Ichikawa H., Kaneda Y., et al. A novel strategy of decoy transfection against nuclear factor-kappaB in myocardial preservation. Ann. Thorac. Surg. 71 (2001) 624-629
132. Sakurai H., Chiba H., Miyoshi H., Sugita T., and Toriumi W. I kappa B kinases phosphorylate NF-kappa B p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 274 (1999) 30353-30356
133. Sakurai H., Suzuki S., Kawasaki N., Nakano H., Okazaki T., Chino A., et al. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappa B p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J. Biol. Chem. 278 (2003) 36916-36923
134. Sanada S, Takashima S, Sakata Y, Asakura M, Terada N. Inhibition of p38 mitogen-activated protein kinase blunts the infarct size-limiting effect of ischemic preconditioning in the in vivo canine heart. Circulation 199;100:492.
135. Sasaki H., Galang N., and Maulik N. Redox regulation of NF-kappaB and AP-1 in ischemic reperfused heart. Antioxid. Redox Signal. 1 (1999) 317-324
136. Sawa Y., Morishita R., Suzuki K., Kagisaki K., Kaneda Y., Maeda K., et al. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury. Circulation 96 (1997) II-4
137. Schmitz M.L., Mattioli I., Buss H., and Kracht M. NF-kappa B: a multifaceted transcription factor regulated at several levels. ChemBioChem 5 (2004) 1348-1358
138. Schoonbroodt S., Ferreira V., Best-Belpomme M., Boelaert J.R., Legrand-Poels S., Korner M., et al. Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. J. Immunol. 164 (2000) 4292-4300
139. Schulz R., Belosjorow S., Gres P., Jansen J., Michel M.C., and Heusch G. p38 MAP kinase is a mediator of ischemic preconditioning in pigs. Cardiovasc. Res. 55 (2002) 690-700
140. Shioi T., Matsumori A., Kakio T., Kihara Y., and Sasayama S. Proinflammatory cytokine inhibitor prolongs the survival of rats with heart failure induced by pressure overload. Jpn. Circ. J. Engl. Ed. 65 (2001) 584-585
141. Sizemore N., Lerner N., Dombrowski N., Sakurai H., and Stark G.R. Distinct roles of the I kappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF kappa B) from I kappa B and in phosphorylating the p65 subunit of NF-kappa B. J. Biol. Chem. 277 (2002) 3863-3869
142. Spiecker M., Darius H., Kaboth K., Hubner F., and Liao J.K. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J. Leukocyte Biol. 63 (1998) 732-739
143. Spiecker M., Peng H.B., and Liao J.K. Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J. Biol. Chem. 272 (1997) 30969-30974
144. Stangl K., Gunther C., Frank T., Lorenz M., Meiners S., Ropke T., et al. Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochem. Biophys. Res. Commun. 291 (2002) 542-549
145. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia reperfusion injury; relationship to ischemic preconditioning. Basic Res. Cardiol. 97 (2002) 276-285
146. SuYang H., Phillips R., Douglas I., and Ghosh S. Role of unphosphorylated, newly synthesized I kappa B beta in persistent activation of NF-kappa B. Mol. Cell. Biol. 16 (1996) 5444-5449
147. Swaroop N., Chen F., Wang L., Dokka S., Toledo D., and Rojanasakul Y. Inhibition of nuclear transcription factor-kappaB by specific IkappaB kinase peptide inhibitor. Pharm. Res. 18 (2001) 1631-1633
148. Tegethoff S., Behlke J., and Scheidereit C. Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is obligatory for IKK complex activity and NF-kappaB activation. Mol. Cell. Biol. 23 (2003) 2029-2041
149. Thompson J.E., Phillips R.J., Erdjument-Bromage H., Tempst P., and Ghosh S. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 80 (1995) 573-582
150. Tomita N., Morishita R., Tomita S., Yamamoto K., Aoki M., Matsushita H., et al. Transcription factor decoy for nuclear factor-kappa B inhibits tumor necrosis factor-alpha-induced expression of interleukin-6 and intracellular adhesion molecule-1 in endothelial cells. J. Hypertens. 16 (1998) 993-1000
151. Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 14: 206-10.
152. TorreAmione, G., Kapadia, S., Lee, J., Durand, J.B., Bies, R.D., Young, J.B., Mann D.L. 1996. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1999; 93:704-11.
153. Traenckner E.B., and Baeuerle P.A. Appearance of apparently ubiquitin-conjugated I kappa B-alpha during its phosphorylation-induced degradation in intact cells. J. Cell Sci., Suppl. 19 (1995) 79-84
154. Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., and Baeuerle P.A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 14 (1995) 2876-2883
155. Traenckner E.B., Wilk S., and Baeuerle P.A. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J. 13 (1994) 5433-5441
156. Trescher K., Bernecker O., Fellner B., Gyongyosi M., Krieger S., Demartin R., et al. Adenovirus-mediated overexpression of inhibitor kappa B-alpha attenuates postinfarct remodeling in the rat heart. Eur. J. Cardio-thorac. Surg. 26 (2004) 960-967
157. Valen G., Yan Z.Q., and Hansson G.K. Nuclear factor kappa-B and the heart. J. Am. Coll. Cardiol. 38 (2001) 307-314
158. Vermeulen L., De Wilde G., Notebaert S., Vanden Berghe W., and Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappa B p65 subunit. Biochem. Pharmacol. 64 (2002) 963-970
159. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., and Haegeman G. Transcriptional activation of the NF-kappa B p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 22 (2003) 1313-1324
160. Wang S., Kotamraju S., Konorev E., Kalivendi S., Joseph J., and Kalyanaraman B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem. J. 367 (2002) 729-740
161. Weinbrenner C., Sarvary L., Rothe M., and Strasser R.H. p38 MAPK-activation during the infarct-inducing ischemia is essential for the protection of ischemic preconditioning. Circulation 106 (2002) 193
162. Whiteside S.T., Epinat J.C., Rice N.R., and Israel A. I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. EMBO J. 16 (1997) 1413-1426
163. Wright G., Singh I.S., Hasday J.D., Farrance I.K., Hall G., Cross A.S., et al. Endotoxin stress-response in cardiomyocytes: NF-kappa B activation and tumor necrosis factor-alpha expression. Am. J. Physiol.: Heart Circ. Physiol. 282 (2002) H872-H879
164. Xuan Y.T., Tang X.L., Banerjee S., Takano H., Li R.C.X., Han H., et al. Nuclear factor-kappa B plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ. Res. 84 (1999) 1095-1109
165. Yada M., Shimamoto A., Hampton C.R., Chong A.J., Takayama H., Rothnie C.L., et al. FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg. 128 (2004) 588-594
166. Yamamoto Y., Verma U.N., Prajapati S., Kwak Y.T., and Gaynor R.B. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 423 (2003) 655-659
167. Yamamoto Y., Yin M.J., Lin K.M., and Gaynor R.B. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 274 (1999) 27307-27314
168. Yanazume T., Hasegawa K., Morimoto T., Kawamura T., Wada H., Matsumori A., et al. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol. Cell. Biol. 23 (2003) 3593-3606
169. Yang F., Yamashita J., Tang E., Wang H.L., Guan K., and Wang C.Y. The zinc finger mutation C417R of I-kappa B kinase gamma impairs lipopolysaccharide- and TNF-mediated NF-kappa B activation through inhibiting phosphorylation of the I-kappa B kinase beta activation loop. J. Immunol. 172 (2004) 2446-2452
170. Yeh S.H., Lin C.H., and Gean P.W. Acetylation of nuclear factor-kappa B in rat amygdala improves long-term but not short-term retention of fear memory. Mol. Pharmacol. 65 (2004) 1286-1292
171. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
172. Yokoseki O., Suzuki J., Kitabayashi H., Watanabe N., Wada Y., Aoki M., et al. cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ. Res. 89 (2001) 899-906
173. Yokoyama T., Rossen R.D., Hazarika P., and Mann D.L. Cellular mechanism for the negative inotropic effects of tumor-necrosis-factor-alpha in the adult heart. Circulation 88 (1993) 238
174. Yokoyama T., Vaca L., Rossen R.D., Durante W., Hazarika P., and Mann D.L. Cellular basis for the negative inotropic effects of tumor-necrosis-factor-alpha in the adult mammalian heart. J. Clin. Invest. 92 (1993) 2303-2312
175. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., and Karin M. The I kappa B kinase complex (IKK) contains two kinase subunits, IKK alpha and IKK beta, necessary for I kappa B phosphorylation and NF-kappa B activation. Cell 91 (1997) 243-252
176. Zhang J., Ping P.P., Vondriska T.M., Tang X.L., Wang G.W., Cardwell E.M., et al. Cardioprotection involves activation of NF-kappa B via PKC-dependent tyrosine and serine phosphorylation of I kappa B-alpha. Am. J. Physiol.: Heart Circ. Physiology. 285 (2003) H1753-H1758
177. Zhang M., Xu Y.J., Saini H.K., Turan B., Liu P.P., and Dhalla N.S. TNF-alpha as a potential mediator of cardiac dysfunction due to intracellular Ca2+-overload. Biochem. Biophys. Res. Commun. 327 (2005) 57-63
178. Zhao S.P., and Zeng L.H. Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia. Int. J. Cardiol. 58 (1997) 257-261
179. Zhong H., SuYang H., Erdjument-Bromage H., Tempst P., and Ghosh S. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 89 (1997) 413-424
180. Zhong H.H., Voll R.E., and Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell 1 (1998) 661-671